{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:55:31Z","timestamp":1788335731880,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1124\/mol.108.051110","type":"journal-article","created":{"date-parts":[[2008,10,17]],"date-time":"2008-10-17T00:45:27Z","timestamp":1224204327000},"page":"218-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Intracellular Activation and Deactivation of Tasidotin, an Analog of Dolastatin 15: Correlation with Cytotoxicity"],"prefix":"10.1016","volume":"75","author":[{"given":"Ruoli","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Edler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Bonate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry D.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Pettit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Ludue\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Hamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/mol.108.051110_REF1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s002800050475","article-title":"Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay","volume":"38","author":"Aherne","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/mol.108.051110_REF2","first-page":"1021","article-title":"Dolastatin 15 induces apoptosis and bcl-2 phosphorylation in small cell lung cancer cell lines","volume":"18","author":"Ali","year":"1998","journal-title":"Anticancer Res"},{"key":"10.1124\/mol.108.051110_REF3","doi-asserted-by":"crossref","first-page":"17141","DOI":"10.1016\/S0021-9258(17)44880-0","article-title":"Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites","volume":"265","author":"Bai","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.108.051110_REF4","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/0006-2952(90)90613-P","article-title":"Dolastatin 10, a powerful cytostatic peptide derived from a marine animal: inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain","volume":"39","author":"Bai","year":"1990","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/mol.108.051110_REF5","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1016\/0006-2952(92)90153-A","article-title":"Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia: interaction with tubulin and effects on cellular microtubules","volume":"43","author":"Bai","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/mol.108.051110_REF6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/jnci\/85.6.483","article-title":"Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15","volume":"85","author":"Beckwith","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1124\/mol.108.051110_REF7","first-page":"3085","article-title":"LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis","volume":"55","author":"de Arruda","year":"1995","journal-title":"Cancer Res"},{"key":"10.1124\/mol.108.051110_REF8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1385\/CBB:38:1:1","article-title":"Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin","volume":"38","author":"Hamel","year":"2003","journal-title":"Cell Biochem Biophys"},{"key":"10.1124\/mol.108.051110_REF9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/1568011023354263","article-title":"Antimitotic peptides and depsipeptides","volume":"2","author":"Hamel","year":"2002","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"10.1124\/mol.108.051110_REF10","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1021\/bi00313a026","article-title":"Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles","volume":"23","author":"Hamel","year":"1984","journal-title":"Biochemistry"},{"key":"#cr-split#-10.1124\/mol.108.051110_REF11.1","unstructured":"Haupt A, Emling F, and Romerdahl C (1998) inventors"},{"key":"#cr-split#-10.1124\/mol.108.051110_REF11.2","unstructured":"BASF Aktiengesellschaft, assignee. Antitumor peptides. U.S. patent 5,831,002. 1998 Nov 3."},{"key":"10.1124\/mol.108.051110_REF12","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/jnci\/83.22.1672","article-title":"Antineoplastic dolastatins: potent inhibitors of hematopoietic progenitor cells","volume":"83","author":"Jacobsen","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1124\/mol.108.051110_REF13","first-page":"490","article-title":"Phase I clinical and pharmacokinetic study of LU103793 (cemadotin hydrochloride) as an intravenous bolus injection in patients with metastatic solid tumors: a study of the AIO Phase I and APOH Group of the German Cancer Society","volume":"19","author":"Mross","year":"1996","journal-title":"Onkologie"},{"key":"10.1124\/mol.108.051110_REF14","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1023\/A:1008430515881","volume":"9","author":"Mross","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1124\/mol.108.051110_REF15","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1021\/jo00287a003","article-title":"Isolation and structure of the cytostatic linear depsipeptide dolastatin 15","volume":"54","author":"Pettit","year":"1989","journal-title":"J Org Chem"},{"key":"10.1124\/mol.108.051110_REF16","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1021\/ja00196a061","article-title":"The absolute configuration and synthesis of natural (-)- dolastatin 10","volume":"111","author":"Pettit","year":"1989","journal-title":"J Am Chem Soc"},{"key":"10.1124\/mol.108.051110_REF17","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1021\/ja00017a061","article-title":"Antineoplastic agents. 220. Synthesis of natural (-)-dolastatin 15","volume":"113","author":"Pettit","year":"1991","journal-title":"J Am Chem Soc"},{"key":"10.1124\/mol.108.051110_REF18","doi-asserted-by":"crossref","first-page":"12097","DOI":"10.1016\/S0040-4020(01)89562-4","article-title":"A convenient synthetic route to dolastatin 15","volume":"50","author":"Pettit","year":"1994","journal-title":"Tetrahedron"},{"key":"10.1124\/mol.108.051110_REF19","first-page":"47","article-title":"Synthesis and cancer cell growth inhibitory studies of dolastatin 15 structural modifications","volume":"13","author":"Pettit","year":"1998","journal-title":"Anticancer Drug Des"},{"key":"10.1124\/mol.108.051110_REF20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00018-002-8427-5","article-title":"The prolyl oligopeptidase family","volume":"59","author":"Polg\u00e1r","year":"2002","journal-title":"Cell Mol Life Sci"},{"key":"10.1124\/mol.108.051110_REF21","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1158\/0008-5472.CAN-06-3065","article-title":"Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate","volume":"67","author":"Ray","year":"2007","journal-title":"Cancer Res"},{"key":"10.1124\/mol.108.051110_REF22","first-page":"1048","article-title":"Dolastatin 10 and dolastatin 15: effects of two natural peptides on growth and differentiation of leukemia cells","volume":"6","author":"Steube","year":"1992","journal-title":"Leukemia"},{"key":"10.1124\/mol.108.051110_REF23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s002800000152","article-title":"A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion","volume":"46","author":"Supko","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/mol.108.051110_REF23a","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1200\/JCO.1998.16.8.2770","article-title":"Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies","volume":"16","author":"Villalona-Calero","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1124\/mol.108.051110_REF25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1471-4159.1983.tb11815.x","article-title":"Inhibition of rabbit brain prolyl endopeptidase by N-benzyloxycarbonyl-prolyl-prolinal, a transition state aldehyde inhibitor","volume":"41","author":"Wilk","year":"1983","journal-title":"J Neurochem"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24146688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24146688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.108.051110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T10:27:10Z","timestamp":1740047230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24146688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0026895X24146688"],"URL":"https:\/\/doi.org\/10.1124\/mol.108.051110","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intracellular Activation and Deactivation of Tasidotin, an Analog of Dolastatin 15: Correlation with Cytotoxicity","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.108.051110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"U.S. Government work not protected by U.S. copyright","name":"copyright","label":"Copyright"}]}}